Loading
companiesCompany
Lumicell
MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends.
Overview
Lumicell, based in Newton, Massachusetts, and founded in 2008, is the MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends. Its pegulicianine, sold as Lumisight, and the Lumicell Direct Visualization System were approved by the FDA in April 2024 after the INSITE trial, making the combination the first optical imaging agent approved for breast cancer surgery. OnCo links it to HR-positive, triple-negative and HER2-positive breast cancer, fluorescence-guided surgery and optical imaging, and to the pegulicianine record. Whether intraoperative imaging reduces re-operations enough to justify its cost and time is the open question. Pegulicianine has its own page.
Headquarters
Newton, MA, US
Scorecard
All companies#388of 1244 companies, score 9
- approved products +6
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Stage
Growth stage
Website
Founded
2008
ApprovedProtease-activated fluorescent imaging agent
Pegulicianine · Lumisight
A cavity-imaging dye used during breast lumpectomy to spot leftover tumour before the operation ends, reducing second surgeries.
Similar pages
- Key paperIntraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery
Shares Pegulicianine, INSITE.
- CompanyPerimeter Medical Imaging AI
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyNearWave
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyStryker
Shares Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Fluorescence-guided surgery.
- CompanyKarl Storz
Shares Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Fluorescence-guided surgery.
- IdeaReal-time margin assessment and image-guided surgery as the global standard
Shares Optical & fluorescence imaging, Fluorescence-guided surgery, HR-positive / HER2-negative breast cancer.
- CompanyOn Target Laboratories
Shares Optical & fluorescence imaging, Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath), Fluorescence-guided surgery.
- TrialGleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
cancers
fronts
technologies
drugs
ApprovedProtease-activated fluorescent imaging agent
Pegulicianine · Lumisight